Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Dr. Reddy's Laboratories Ltd (RDY)

Dr. Reddy's Laboratories Ltd (RDY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 12,230,262
  • Shares Outstanding, K 166,285
  • Annual Sales, $ 2,561 M
  • Annual Income, $ 258,510 K
  • 60-Month Beta 0.45
  • Price/Sales 4.73
  • Price/Cash Flow 24.12
  • Price/Book 5.22
Trade RDY with:

Options Overview

Details
  • Implied Volatility 30.69%
  • Historical Volatility 15.25%
  • IV Percentile 9%
  • IV Rank 21.51%
  • IV High 62.02% on 03/23/21
  • IV Low 22.11% on 08/19/20
  • Put/Call Vol Ratio 4.00
  • Today's Volume 25
  • Volume Avg (30-Day) 40
  • Put/Call OI Ratio 0.81
  • Today's Open Interest 894
  • Open Int (30-Day) 755

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year 0.46
  • Growth Rate Est. (year over year) +217,073.91%

Price Performance

See More
Period Period Low Period High Performance
1-Month
71.37 +1.01%
on 05/28/21
74.42 -3.13%
on 06/16/21
+0.09 (+0.12%)
since 05/17/21
3-Month
57.54 +25.29%
on 03/18/21
74.42 -3.13%
on 06/16/21
+12.35 (+20.67%)
since 03/17/21
52-Week
51.12 +41.02%
on 07/07/20
74.42 -3.13%
on 06/16/21
+18.65 (+34.90%)
since 06/17/20

Most Recent Stories

More News
Global Response Aid Reports Midyear Sales Results for COVID Drug

, UAE, /PRNewswire/ -- Healthcare solutions provider Global Response Aid (GRA) today reported seven-month global sales figures for its anti-viral tablet Avigan®/Reeqonus™, a drug being used in several...

RDY : 72.09 (-1.99%)
Dr. Reddy's (RDY) Q4 Earnings Decline Y/Y, Sales Increase

Dr. Reddy's (RDY) earnings decline while sales grow year over year in fourth-quarter fiscal 2021.

RDY : 72.09 (-1.99%)
ADPT : 39.82 (+4.90%)
ADVM : 3.73 (+2.19%)
MIST : 6.11 (+2.17%)
Dr. Reddy's Laboratories Announces the Launch of Ertapenem for Injection in the U.S. Market

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy's") today announced the launch of Ertapenem for Injection,...

RDY : 72.09 (-1.99%)
Amarin (AMRN) Q1 Earnings Top, Vascepa Sales Hit by COVID-19

Amarin's (AMRN) Vascepa sales get hit by COVID-19 and by severe winter storms and power outages in various areas of the United States. Its cost management plan boost the bottom line. Stock up.

TEVA : 10.40 (-1.61%)
RDY : 72.09 (-1.99%)
AMRN : 4.93 (+0.82%)
CDMO : 23.71 (-2.43%)
Dr. Reddy's Laboratories Announces the Launch of Albendazole Tablets, USP in the U.S. Market

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY along with its subsidiaries together referred to as "Dr. Reddy's") today announced the launch of Albendazole Tablets,...

RDY : 72.09 (-1.99%)
Dr. Reddy's Laboratories Gets Emergency Use Authorisation for Sputnik V in India

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) today announced that it has received the permission from the Drug Controller General of India (DCGI) to import the...

RDY : 72.09 (-1.99%)
Dr. Reddy's Laboratories Announces the Launch of a Generic Version of Sapropterin Dihydrochloride Powder for Oral Solution, 100 mg in the U.S. Market

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY along with its subsidiaries together referred to as "Dr. Reddy's") today announced the launch of Sapropterin Dihydrochloride...

RDY : 72.09 (-1.99%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY

NEW YORK, NY / ACCESSWIRE / March 9, 2021 / Pomerantz LLP is investigating claims on behalf of investors of Dr. Reddy's Laboratories Limited ("Dr. Reddy's" or the "Company") (NYSE:RDY). Such investors...

RDY : 72.09 (-1.99%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY

New York, New York--(Newsfile Corp. - March 7, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Dr. Reddy's Laboratories Limited("Dr. Reddy's" or the "Company") (NYSE: RDY). Such...

RDY : 72.09 (-1.99%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY

, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Dr. Reddy's Laboratories Limited ("Dr. Reddy's" or the "Company") (NYSE: RDY).  Such investors are advised to contact...

RDY : 72.09 (-1.99%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Doctor Reddy's is an emerging global pharmaceutical company with proven research capabilities. They are vertically integrated with a presence across the pharmaceutical value chain. They produce finished dosage forms, active pharmaceutical ingredients and biotechnology products and market them globally,...

See More

Key Turning Points

3rd Resistance Point 73.41
2nd Resistance Point 72.91
1st Resistance Point 72.50
Last Price 72.09
1st Support Level 71.59
2nd Support Level 71.09
3rd Support Level 70.68

See More

52-Week High 74.42
Last Price 72.09
Fibonacci 61.8% 65.52
Fibonacci 50% 62.77
Fibonacci 38.2% 60.02
52-Week Low 51.12

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar